VanEck Pharmaceutical ETF
Key Statistics
Historical Performance
Total return including reinvested distributions, from adjusted closing prices.
Price History
Price history is being compiled for this fund.
Top Holdings
Top 25 holdings as of Mar 31, 2026 · source: SEC N-PORT. Full holdings & prospectus →
About PPH
The Fund normally invests at least 80% of its total assets in securities that comprise the Fund’s benchmark index. The Pharmaceutical Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. To be initially eligible for the Pharmaceutical Index, companies must generate at least 50% of their revenues from pharmaceuticals. Pharmaceuticals include companies engaged primarily in research (including research contractors) and development as well as production, marketing and sales of pharmaceuticals (excluding pharmacies). Of the largest 50 stocks in the pharmaceutical industry by full market capitalization, the top 25 by free-float market capitalization ( i.e. , includes only shares that are readily available for trading in the market) and three month average daily trading volume are included in the Pharmaceutical Index. As of December 31, 2019, the Pharmaceutical Index included 25 securities of companies with a market capitalization range of between approximately $2.0 billion and $383.9 billion and a weighted average market capitalization of $108.1 billion. As of September 30, 2019, approximately 30.2% of the Fund’s assets were invested in securities of European issuers. These amounts are subject to change. The Fund’s 80% investment policy is non-fundamental and may be changed without shareholder approval upon 60 days’ prior written notice to shareholders. The Fund, using a “passive” or indexing investment approach, attempts to approximate the investment performance of the Pharmaceutical Index by investing in a portfolio of securities that generally replicates the Pharmaceutical Index. Unlike many investment companies that try to “beat” the performance of a benchmark index, the Fund does not try to “beat” the Pharmaceutical Index and does not seek temporary defensive positions when markets decline or appear overvalued. Indexing may eliminate the chance that the Fund will substantially outperform the Pharmaceutical Index but also may reduce some of the risks of active management, such as poor security selection. The Fund is classified as a non-diversified fund under the Investment Company Act of 1940, as amended (the “1940 Act”) and, therefore, may invest a greater percentage of its assets in a particular issuer. The Fund may concentrate its investments in a particular industry or group of industries to the extent that the Pharmaceutical Index concentrates in an industry or group of industries. As of September 30, 2019, the Fund was concentrated in the health care sector and the pharmaceutical industry.
PPH News
- VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style?
- Technical Reactions to PPH Trends in Macro Strategies
- VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style?
- Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
- Trading the Move, Not the Narrative: (PPH) Edition
- Will Generic Drug Tariffs Impact Pharma ETFs?
- Novartis chart may soon 'complete a well-defined bullish reversal,' Cappelleri says
- Is the VanEck Pharmaceutical ETF or State Street Health Care ETF the Better Buy for Your Portfolio?
- Is the VanEck Pharmaceutical ETF or State Street Health Care ETF the Better Buy for Your Portfolio?
- Healthcare of Ontario Pension Plan Trust Fund Sells 469,000 Shares of VanEck Pharmaceutical ETF $PPH
- Concentrated Pharma Exposure or Broader Global Healthcare? PPH vs. IXJ
- Concentrated Pharma Exposure or Broader Global Healthcare? PPH vs. IXJ
Data for PPH is aggregated from third-party providers (Tiingo, Nasdaq, Finnhub) and SEC filings, may be delayed at least 20 minutes, and may be incomplete or contain errors. Nothing here is investment advice. Verify with the official prospectus before investing.